Allozyne Inc.

Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaog

Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent m

It took 20 years to realize the dream of the "magic bullet" of an antibody-drug conjugate: a targeted cell-killing small molecule that rides right into a tumor on the back of an antibody, avoiding the

Poniard Pharmaceuticals, which is hoping to provide a way out for shareholders and complete a merger with privately held Allozyne before the end of 2011, has granted an undisclosed party the worldwide